Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer

被引:2
作者
Nasser, Nicola J. [1 ]
Saibishkumar, Elantholi P. [2 ]
Wang, Yinkun [3 ]
Chung, Peter W. M. [4 ]
Breen, Stephen L. [5 ]
机构
[1] NYC Hlth Hosp, Elmhurst Hosp Ctr, Dept Radiat Oncol, Queens, NY 11432 USA
[2] British Columbia Canc Agcy, Victoria, BC, Canada
[3] Princess Margaret Canc Ctr, Dept Radiat Phys, Radiat Med Program, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
关键词
statistical process control; brachytherapy; prostate; quality control; dosimetry; RADIATION-THERAPY; AMERICAN-BRACHYTHERAPY; I-125; SEEDS; INTERMEDIATE; RISK; DOSIMETRY; VOLUME;
D O I
10.5114/jcb.2022.119513
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Variations in dosimetric outcomes among patients treated with low-dose-rate brachytherapy for prostate cancer exist, even when implants are within dose constraints. Here, we used control charts to investigate reasons for intra-patient dosimetric variability. Material and methods: Univariate and multivariate control charts for prostate V-100 (percentage of prostate volume that received 100% of prescribed radiation dose), D-90 (radiation dose to 90% of prostate volume), and RV100 (rectal wall volume that received 100% of prescribed radiation dose) were generated for 212 consecutive prostate cancer patients implanted with iodine-125 (I-125) radioactive seeds at the Princess Margaret Cancer Centre. Control limits were calculated based on the first fifty implants. Data points that were out of control were identified, and their pre-treatment and post-treatment dosimetric and clinical parameters were compared to data points that were in-control, using Student's t-test. Results: All implants were clinically acceptable. Twelve data points exceeded multivariate control limits. Ten of those points fell below the lower control limit of V-100 control chart. Average prostate edema in the 10 out-of-control patients on both multivariate and V(100 )charts was 8.3%, as compared to 0.4% for in-control patients (p < 0.04). Two patients were observed to be out-of-control on multivariate control chart, but not on V-100 control chart, and were found to have a reduction in prostate volume of 19.1% and 20.1% at one month after seed implant, compared to prostate volumes of pre-implantation evaluations. Conclusions: Control charts helped in identifying cases with out-of-control variability in post-plan prostate dosimetry. Post-treatment prostatic edema and contraction are important factors predicting variability in patients treated with I-125 permanent seed brachytherapy.
引用
收藏
页码:354 / 363
页数:10
相关论文
共 50 条
  • [21] The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer
    Shaikh, Talha
    Wang, Lora
    Ruth, Karen
    Hallman, Mark
    Chen, David Y.
    Greenberg, Richard E.
    Li, Jinsheng
    Crawford, Kevin
    Horwitz, Eric M.
    BRACHYTHERAPY, 2016, 15 (02) : 156 - 162
  • [22] Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer
    Okamoto, Keisei
    Okuyama, Kahori
    Kohno, Naoaki
    Tsugawa, Takuya
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (01) : 6 - 11
  • [23] Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
    Yamoah, Kosj
    Eldredge-Hindy, Harriet B.
    Zaorsky, Nicholas G.
    Palmer, Joshua D.
    Doyle, Laura A.
    Sendecki, Jocelyn A.
    Hesney, Adam A.
    Harper, Logan
    Repka, Michael
    Showalter, Timothy N.
    Hurwitz, Mark D.
    Dicker, Adam P.
    Den, Robert B.
    BRACHYTHERAPY, 2014, 13 (05) : 456 - 464
  • [24] Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation
    Meraouna, Y.
    Blanchard, P.
    Losa, S.
    Labib, A.
    Krhili, S.
    Pommier, P.
    Crehange, G.
    Flam, T.
    Cosset, J. -m.
    Kissel, M.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2024, 48
  • [25] Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer
    Langley, Stephen
    Uribe, Jennifer
    Uribe-Lewis, Santiago
    Franklin, Adrian
    Perna, Carla
    Horton, Alex
    Cunningham, Melanie
    Higgins, Donna
    Deering, Claire
    Khaksar, Sara
    Laing, Robert
    BJU INTERNATIONAL, 2020, 125 (03) : 383 - 390
  • [26] The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy
    Echevarria, Michelle I.
    Naghavi, Arash O.
    Venkat, Puja S.
    Abuodeh, Yazan A.
    Chevere, Carlos
    Yamoah, Kosj
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (05) : 386 - 390
  • [27] Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Yamaguchi, Nanae
    Horie, Shigeo
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (03) : 167 - 174
  • [28] Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer
    Pos, FJ
    Horenblas, S
    Lebesque, J
    Moonen, L
    Schneider, C
    Sminia, P
    Bartelink, H
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (03): : 696 - 705
  • [29] Equivalent uniform dose, D90, and V100 correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer
    Miles, Edward F.
    Nelson, John W.
    Alkaissi, Ali K.
    Das, Shiva
    Clough, Robert W.
    Anscher, Mitchell S.
    Oleson, James R.
    BRACHYTHERAPY, 2008, 7 (02) : 206 - 211
  • [30] Low-dose-rate brachytherapy for prostate cancer stands the test of time - the Swiss experience
    Langley, Stephen E. M.
    BJU INTERNATIONAL, 2020, 125 (06) : 750 - 751